-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Cuz1nXOi3C/dsjc10YLGmSERYIStilUC+Vj3GnOsmaRVEwxZf33p7yVUkzYiXsao
 IEzcpqCGhLRiJ93pFSCT7Q==

<SEC-DOCUMENT>0001129928-09-000009.txt : 20090323
<SEC-HEADER>0001129928-09-000009.hdr.sgml : 20090323
<ACCEPTANCE-DATETIME>20090323153656
ACCESSION NUMBER:		0001129928-09-000009
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090320
FILED AS OF DATE:		20090323
DATE AS OF CHANGE:		20090323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09698752

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<html>
  <head>
    <title>form6-k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div><br><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule&#160;13a-16 or 15d-16</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of&#160;March 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number 000-31062</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210,
1167 Kensington Crescent NW</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta, Canada T2N 1X7</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&#160;20-F or Form&#160;40-F.</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NUMBER</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="7%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="69%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News
      Release Dated March 20, 2009 -&#160;Oncolytics Biotech&#174; Inc. Collaborators
      Update Combination REOLYSIN&#174; and Docetaxel Trial Results at Replicating
      Oncolytic Virus Meeting<br></font><br>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">&#160;</div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </div>
                  </div><br></div><br></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" colspan="3" valign="top" width="39%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;March
      20, 2009</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="2%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="36%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;Doug
      Ball</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Doug
      Ball</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Financial Officer</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><img src="ex99110.jpg" alt=""><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">210, 1167
Kensington Cr. N.W</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Canada
T2N 1X</font><br></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -18pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
IMMEDIATE RELEASE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech&#174; Inc.&#160;Collaborators Update Combination</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">REOLYSIN</font>&#174;<font style="DISPLAY: inline; FONT-WEIGHT: bold"> and Docetaxel Trial Results at
Replicating Oncolytic Virus Meeting</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- March 20,
2009</font> &#8211;Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">today
announced updated clinical results from its U.K. combination REOLYSIN&#174; and
docetaxel clinical trial for patients with advanced cancers.&#160;&#160;The
principal investigator for the trial is Professor&#160;Hardev&#160;Pandha of the
Royal Surrey County Hospital, U.K. The results were presented at the Fifth
International Meeting on Replicating Oncolytic Virus
Therapeutics.&#160;&#160;The meeting is being held in Banff, Alberta from March
18th to 22nd, 2009.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Twenty-four
patients were treated in the trial, with 17 evaluable for response. Fifteen of
the 17 evaluable patients experienced Stable Disease (SD) or better, including
five patients who experienced minor and Partial Responses (PR), giving a
clinical benefit rate (SD + PR + Complete Response (CR)) of 88%.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Heavily
pretreated patients are the most difficult to treat,&#8221; said Dr. Karl Mettinger,
Chief Medical Officer for Oncolytics.&#160;&#160;&#8220;It is very encouraging to
observe such a robust response rate, including a significant objective tumour
response in this group.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;In
future, we plan to combine docetaxel with REOLYSIN&#174; in patients with metastatic
sarcoma,&#8221; added Dr. Mettinger.&#160;&#160;&#8220;Both REOLYSIN&#174; and docetaxel have
been demonstrated to be active against sarcoma, and there is ample preclinical
evidence demonstrating that the combination may be synergistic in this patient
group.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Phase
I trial (REO 010) had two components.&#160;&#160;The first was an open-label,
dose-escalating, non-randomized study of REOLYSIN&#174; given intravenously to
patients with docetaxel every three weeks. In this portion of the trial,
standard dosages of docetaxel were delivered to patients with escalating dosages
of REOLYSIN&#174; intravenously.&#160;&#160;&#160;&#160;The second component of the
trial included the enrolment of additional patients at the top dose of REOLYSIN&#174;
in combination with a standard dosage of docetaxel.&#160;&#160;Eligible patients
included those who have been diagnosed with advanced or metastatic solid tumours
that are refractory (have not responded) to standard therapy or for which no
curative standard therapy exists.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
poster presentation will be available on the Oncolytics website today at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
Oncolytics Biotech Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical
program includes a variety of Phase I/II and Phase II human trials using
REOLYSIN&#174;, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy.&#160;&#160;For further information
about Oncolytics, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This
press release contains forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements, including the implication of the materials presented at this meeting
with respect to REOLYSIN&#174;, the Company&#8217;s expectations related to the results of
trials investigating delivery of REOLYSIN&#174;, the Company&#8217;s analysis of the
results of the REOLYSIN&#174;/docetaxel trial and the Company&#8217;s belief as to the
potential of REOLYSIN&#174; as a cancer therapeutic, involve known and unknown risks
and uncertainties, which could cause the Company&#8217;s actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of REOLYSIN&#174; as a cancer
treatment, the success and timely completion of clinical studies and trials, the
Company&#8217;s ability to successfully commercialize REOLYSIN&#174;, uncertainties related
to the research and development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment. Investors
should consult the Company&#8217;s quarterly and annual filings with the Canadian and
U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except as
required by applicable laws.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
FURTHER INFORMATION PLEASE CONTACT:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy
      Ward</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210,
      1167 Kensington Cr NW</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      Alberta T2N 1X7</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.670.7377</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.283.0858</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Equicom Group</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick
      Hurst</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325,
      300 5th Ave. SW</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      Alberta T2P 3C4</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.538.4845</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.237.6916</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="28%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Investor Relations Group</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erika
      Moran</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11
      Stone St, 3rd Floor</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New
      York, NY&#160;&#160;10004</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99110.jpg
<TEXT>
begin 644 ex99110.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!X`````0```'@````!````4&%I;G0N3D54('8T+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHK-\7>+_#?@/P[>>+O&&N6NFZ7IUNT]]?WLPCB@C49+,QZ"
M@"^\R*,YS6-XS^)7@#X=:;_;'Q`\::3HEIN"BYU;48[>,DG`&Z0@<GBO@?XX
M_P#!4/X]?'_XF7'P%_8!\#273.[1Q^)A:B6XN%'WI8DD`CMXASB27)/!PO0U
M?`'_``1G^+/Q8U)/'7[7W[0M]+?7`,ES9:=,U[=*6W;E-S<$HI'R'Y49<Y'(
M`:O.EC959<N'@Y>>R-/9V^)V/JIO^"E'[#$;M&_[2/A_<K$'#2$?F$YK9\$_
MMT_L@_$?5#HG@W]H/PQ<W>Z-5@EU%8&=G;:JKYNW>Q)QA<FO)-/_`."+/[$M
MO8PV]WIOB:YE2)5DN7\12*TK`<L0@"@GK@`#G@5A_$7_`((@_LK>(-%^S^`/
M$?B3PY?IN,=VU]]MC)(P-\<HY`Y^ZRGGDT<^96^&/WL3]EW/LRTO[.^@6ZL[
ME)8F'R2QN&5OH1P:E#*W0YK\KO'/[.W[>?\`P3$U4?$;X,>/KCQ)X+MI`UXE
MHDCVR0K("%N[-B1&IW']Y$>-SG<F>?J_]AO_`(*:_"[]K".'P1XBMH?#?CAE
M=O[$>5FAO53&9+:0@;C@Y,1^==K'Y@-U72QU.53V=1.,NSZ^@2IM*ZU/J.BD
M1MRAL=12UW$!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`-D/R$?J:_,3]L3XT_$
M[_@I%^TC!^Q]^SL[P^&]!OIAJE])<XM[UX9%62]F"]88CQ&O)9F!QD@+]=_\
M%*OVA-2_9U_90UWQ-X<N1#K6L,FCZ-+E@T<T^0TBD#ADB65QD@90#.2!7`_\
M$<OV;K'X5?LTQ?%;4[/&M^.F%XTDL?S1V*EEMT'^RPS+GG=YB^@QYN+<L17C
MAUMO+T[&D?<7,>X_LM_LJ_"S]D[X>1^!/AII"B2;;+J^JS$M<:A<!0#([$DA
M<YVIG:HX'J?3Z`,#%%>A"$:<5&*LD9MMN["BBBJ`;,JNA1E!!&""*_/S_@I?
M_P`$[/#WA'PW+^U/^RYH$V@Z[H5VM_KFGZ&SQJ8EQFZMXXQ^ZEC;$C%2H*AF
M(R.?T%J"_L[:_MGL[R!)8949)8I4#*ZD8*D'@@C@@USXBA"O#EEOT?8J,G%W
M1\W?\$TOVTT_:U^#[6?BJ3'B[PPD5MX@+;0+T,I\N[0*!@/M;(P,.K`9&#7T
MQ7Y8>.O!\W_!-?\`X*;^'=7\%3/#X0\6W:-'91LK;;&[F$4]L4&WY8I</'TP
M!&,G#Y_4R)MV>.AK#`5ISA*G/XHNS'.*3NNH^BBBN\@****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`/SI_X+NZW=7=W\,/APT:+:W<U_=O<*#YBL#!#@<XQB4GIU`[<5]_
M>`_"NG>!O!VE^#=(`%KI>G06MN!&J_)'&J`X4`#(&>!BOS\_X+L:9J$'B?X5
M^,Y;?&FV_P#:%O-<[QA9#);2;<?>/RHQX';UP#^AWAW5[#7M#M-;TN;S;6\M
M8Y[:7:1OC=0RM@@$9!!P:\W#I/'UK^7W6-)?PXEVBBBO2,PHHHH`****`/@/
M_@O)X/T.7X4>!_'S6V-3MO$<NGQS*`,P2V[RLIXR</`A'/&6_O5]C?LWZYJW
MBGX!>"/%&O7AN+W4?"&FW-Y,4"^9*]LC,V%``R23P!7R-_P7CU33XO@3X)T6
M2\C%W-XN>XAMBXWO%':2H[@>BM+&">V\>M?6/[+D=Q9_LU_#ZRO+62&:'P3I
M22Q2H59&%I&""IY!&.AKSJ3MCZGHOU*_Y=1/*_\`@IY^T]\4OV4?@;I?Q"^$
MS::NHWGB>&PE.IV9G3RFM[B0X4,N#NC7G/K7FG[$/_!3OQ%X^\=#X%_M9V-A
MH7B74O*G\,ZM:Q^39:E%,JO#'RS`,ZL&C<,5D#`##8#6/^"Z#;OV4_#XZ?\`
M%=V_/_;I=UB^+_\`@GKX8_:X_8<^&'C+P@8-*\?:5\/-,_LS4C\B7R);(5MI
MR.V?NOU0G^Z2*RJO%?6W[-_"MNY7N\EF?3/[9?Q'^(OPA_9H\6_%#X77^G0:
MSH&F&]A?5+5IH6CC=6E4HI!+-'O"\X#$$UQ__!-']I'XE?M3?LZS?$_XK/I[
M:FGB.ZL5_LVT,,?E1I$5^4LW.7;G-?'VA_MW^/K[]EWXG?L6?M6V-[9^-=+\
M)7UKI&J:@");HQ1$_9K@GK*$&4ER1*N.2Q!?Z$_X(B#=^QG<<_\`,Z7_`/Z*
MMZ*6*]OC(J+=K.Z\[@X*$+-'UKKNO:/X6TJZUWQ!J4%G96=N\UW=W4PCCAC4
M99V9N%``Y)KXX'[??[1G[67C74/`7[`'PMTZ33-(N`NI>/?&#,+,X;A8XEY&
M]02N[+%23M7&3Z7_`,%4/"_COQ?^Q-XPTGP!')+<)';7&H6D%L99+BSCN$>5
M%503D!0^1CA#R*\K_P""(7CGX:2?LZZEX`TC68E\3P^(+F^UC3)KM#*\;+$D
M=Q'&/F$6U40DC'F*_/(K2O5D\6J*=DU?_AF))*-SO;KP-_P5BLO.U.U^.GPC
MNY!"/*T]_#EVD;,NX[0V<J6R%))(``P!@Y]M^!MS\=;SP:+S]H/2_#=CKLD[
MDV?A:6>2WAB'"@R3'+N<$G`4#('.,GL57<H;-*/D/UKKI45!WN_ON2W<X']I
M']HSX:_LP?#6[^)WQ.U<P6L'[NSM(2#/?W!&4@A4_><X^@&6)`!-?.GP@^/?
M_!1S]L#2(OBC\'/#'@3X=^#[F%AI;^*EGU"XOV#[2X\O9M3(;!*KG'&X$,>5
M_P""[G@GQ;J_PC\&>-=,GO)-(TG79H]5M8;=FBB::("*XD8<)M*M&,C!,W4'
M&?HK_@GMX\\&_$/]D#P)J?@FVMK:WLM`AT^ZLK=L_9;F!1'+&<@8.X%NF"'!
M!(()XW.=7'.E)M)*_K_PQ25H<QP7BJ'_`(*S>`=&D\66/B7X5^-'L\.WAJPT
M>ZM)KQ>A"2R2!01G=@D9VX!YJ_\`L6_\%*?AU^UCKLGPXU/PK>^&/&5I:R37
M&CW;B2&81D"3R9."2I/*,H8`$\@$CZ4D^7'N*_)W]EZ$>/?^"PE]K_PGO7M]
M,B\8:U?7%Q',9EFM%682_.B@;)7;*@C`$B+EN"9KU*F&J04)7YG;74<4I7/U
MF5@XR*^-_P!@+]MCXY?M'?M-?$3X4?$J?1VTCPPEVVEC3]-:&4&.^,"[VWL&
M^3V'/-?8\8^7=ZU^;G_!(?'_``W-\9^W[J__`/3L:WQ4YQQ%%)VNW?[B4ERL
M_26JFO6FIWVCW5KHNJ+8W<ENZVUXUN)1#(0=KE"0&P<'&1G&,BK3-M[4,-RE
M<UW$GP,/^"BO[3/[*W[3!^$'[=NA:2WAN^&-/\2>'M*DAC\LOA;M<N_F1]!)
M']^/DX./F^SO&'QG^&'@7X7W'QD\3^,["W\-06`O&U@7`>%X6&49"N?,+9`4
M+DL2`,FN>_:E_9:^&'[5GPRG^'/Q(L#E0TNDZM`@^T:;<[2!-$3^14_*PX/M
M^8O[.?[.OQ%^/O[1,O[`/Q%^,^H/X+^'NKZE>W-G;2MY<OV>=()!`&R4+LPQ
MNR(PTC*-S'/D5*E?"SY'[RE\/KYFEE)770^MOV7/VN?VN_VU_CAJ'B/X9:)I
M/A?X0:3?".2_U;26FO;T(>88W\P+YK]6P"L0(!+-C/TU\=-,^.NK^!OLW[/G
MB?0-(\0B\C87GB6QDN+7R.?,4I&0VX\8/08-;OP_^'W@_P"%OA"P\!^`M!M]
M,TC3+=8+*RM4VI&@_F2<DD\DDDDDUM5W4J,U2M.5V]_\D0VN:Z/C/]HGQO\`
M\%//V<O@YK?QI\3?%_X5W]CH4,<EQ9V'AB[$L@>:.(!=T@'5P>?2J/[+WQ3_
M`."FG[5?P>L?C1X2^*WPNTRQO[FYACM-2\,71E5H9GB8G9(1@E<CV/->K?\`
M!4W_`),/^(1_Z<;3_P!+K>L#_@CJN?V#_#?/_,5U3_TMEKCY9+&JGS.UK[E_
M9O8]A_9ZT3]I'1M!OQ^TMXW\,ZUJ<EV#8-X6TR6V@A@"#AO-)9G+9YZ8`]Z\
MW_X*9_M)_$[]E?\`9[M_B9\*&T]-3E\26UB6U.T,\?E/',S?*&7G*+SGUKZ)
M5=O>OCK_`(+A?\F=6/\`V.UE_P"B+FNG$2E2PLG%ZI$P^(]C_8-^-/CG]H3]
MEOPS\7OB/)9MK&J_:Q=FPMC#%^[NYHEVJ6;'RHO<\UT_[0W[0?PV_9G^&UY\
M4OBAK0M;*V&RWMX\-/>SD$I!"F?G=L?0`$D@`FO+?^"31S^P7X(/J=1_].%Q
M7C/_``79\*?$#5_A+X-\4:#9W$V@:/K-P=;\G<4AFDC1;>:0`$`#$R!B1AI%
M'\7&3K3IX%5=W8.7WK'0?#?]JG_@H+^V5)#XK_9L^$OAOP%X,61A'KOCGS;E
M]14LX#Q+&%#*-@!V@@%B`[8Q7=OHG_!5SPX?[6/C;X/>)A'Q_8S:;?60ER<;
MO.!.W;G.,<XQ77?\$]?$OPZ\2_L>^!/^%9WL<EE8>'K>TNX5FWO;W:(/M".-
MQ*MYN]MI.<,.@KVNKHTG4IJ3FW?L]`O9V,3P`OC?_A%+%_B1_9HUPVRMJ:Z.
M)!:K*>66+S"6*CID\G&<#.!\O_MO?\%)/$?[/'QMT3]G3X3_``VLM6\2:J+-
MI+[7;MXK*+[3*8XD'E_,Q)!+,2`HQPW./KNO*OVDOV/?@'^U5IL>F?%[P1'=
M75M$4L-9LY/(O;0$Y(CE7G&>=K;ESR5-:8B%:5&U*5F)-)W9YA<?#W_@JIKE
M]!K\G[0GPNT@PDR1Z+:>&[B:WE\SK%-(_P`[",9VLA7<1SP:Z3X+7_\`P46M
M_&=EH7QYT/X8S>'XYYO[0UW1+R[2[FC&[R_+@(VJ2=@^8GC/>O*)_P#@FK^U
M'\-+-[?]G'_@H%XKL+:(0O;Z5XB+S1ET(&#(KD)'L4`((B#C!X/'GUI_P4&_
M;0_98_:&T_\`9P_:=TKP]XV:ZO[6/[?H:!+MX+F5E21!$%3?EE/EO&IPO?<&
MKC]K[!IU%)7=M[HOEYMC]&`,#%%%%>L9GRM_P5U^`]U\9/V2K_7=)TTW.J^#
MKI=7MEB4%S;JI6Y4<'_EDS/@=?+`S6G_`,$I_C_9?'#]DK1+"\U4S:UX21=&
MUA)"3)B,?N)"2Q+;X=GS9Y97Z8P/I"_M+>^M)+2[A22*6,I)'(N5=3P01W!&
M17Y:^*+7XC_\$?OVO)/&&DZ6VJ_#;QE--Y&GV\Q'FV@<-Y)'W5N;??\`(3\K
M(Q&1N.WS,3_LN*CB/LO27EV9I'WHV/U0R#T-%<W\*OBIX$^,W@FQ^(/PX\0V
MNJ:3J$(>"YM9U?:?XHWVD[74\,IY!&#725Z,9*2NMC,****H`I&95ZFE)P"?
M05\K_P#!1G_@H3H'[*O@I_"'P]U/3=0\>Z@#%;V+3K(=)C9"?M4\8YQC&Q#C
M<2#RJFLJU:%&'-(:3D[(^8_VZ-=C_;B_X*-^%/V;_!R2W6E>'KM-+U.:&1FC
MSO$U])@,H`CC7RRP(8E"!GY<_I[I]I'8VR6D";8XD5(QG.%`P!GO7QE_P28_
M8MU3X3>&+C]I/XMVSGQAXOMB]G'="3SK&SE82,90X!$\K`.V>0,#/WA7VI7'
M@:=1J56IHY._RZ%U))NRZ'D'[97[(WAO]LOX<67PS\5>+=0T6VL=9CU&.ZTR
M.-I'=(I8PI\P$`8D)]>*[KX._#BR^#WPN\/?"O3=2FO+?P]HUMIT%U<`"25(
M8P@=@O`)`R<<5\K_`+=__!17XK_LR_MM_"#]D3X>>#M+N+?XF>&M=U2\UZZ\
M,:MK5Q9-IZQLJ1V.F9FE#[R"W1.IX!KK/^"?_P#P4,/[6GCGXC_!#Q]X<M-"
M\:_#;6([>[L?L]YI\^IV,J*\.H+IFH11WEI$P=%S(&1FSLD;!"]JI04^?J9F
M]^V/_P`$[?@S^V/=V/B'Q+=7>@Z]8;8QKVCQQ^=<6XSB&57!5P"<J2-R\@'!
M(KKOV._V5_#W['WPFD^$WACQ5?:Q;2:O/?\`VS48HTDW2*@*XC`&!L&._->J
MDX&:^</VG_VYM9^`_P"V[^SK^R'I7P_M=0A^-VI^(8M0UNXO61M+ATS3?M0\
MN,+AWD=XQDD`*K<$D8E8>BJOM$O>&VVK,^C3$K`JV"",$$5\Q_%3_@E9^S_X
MT\8M\3/ACK&O?#?Q([EWU+P5?_9D=F8%R8C\J[L'(0J#N)()KZ>KQG]O_P#;
M"L/V#?V4?%G[4>I_##6_%\/AFS63^Q-"`$DKNZQJTLC`K;VZE@TL[96)`S$-
MC%.K1IUE::N";6QR=K^PM\9UNXGO_P#@H1\69[=9%\^!;BT0R)D;EW"+*DC(
MSVSGM7J?P"^`.G?L_:!=^&='^)'B_P`0VEU<":,>+];_`+0DMVQAA'(R!PIX
M)4DC/3&3GY\_:(_;D_:T_91_9SO?VT/BG\$?`&M^`=,T:UU37M"\*^,KG^U]
M*MI)HD<P32VQM]5(20N`/LH)4*I?=NKZM\%>++#QUX4TSQCI5M<Q6NK:=!>V
ML=Y;M#,L<L:NHD1AE'`894\@Y!Y%*G0ITW=`VV2>*O"VA>--!N_"_B?1[;4-
M.U"V:WO;*[B#QS1,,,C*>""*^:K;_@ESX4^'WB&?6/V:OV@O'WPTM;R,"^TG
M0-46>WE<;?G`N`Y!^4=23Z$#BOI+QBOBJ3P[>0^"+C3XM7:V<:=+JL#RVRS$
M?*9$C969,]0&!/3(KXY^`?[:G[;'QG_;P^,?[%=W9?"NQ/P8MO#EUJ.OQ:5J
M3_VM%JELUP4CB-U^X>-4*Y9G#$YP`"*)T*527-):@FT=K?\`_!/7XR^)-%DT
M#QG_`,%"?BG?6ER"EY;PR6\*RQ[LA<A=R\8!(/)SP`<5ZQ^SE^R-\"_V6-"D
MT7X0>#(K*6XB1+_5+AS->7FWH996Y(R20HPHSP!7IBMN&<=Z\\_:Y^,>J?L[
M_LL_$?X_:'H]OJ-YX(\"ZMKUKI]V[+%<R6EG+<+&Y7D*QC`)'(!-*.'I0=T@
M;;/1,`=!7Q[X=_X)*VG@7XD:U\4OAC^UAX[\,:IKEW<RW<ND1VR?)-*96BY0
M[E#'C.3P#UYK:_8N_:O_`&BOVAY?#>I?$2VT:PMM3\.1ZIJEA:?";Q1IJQ&2
M%66*'4=26.WEVO(G.T%U#%5&,CZH!R,TZM"E6:<UML";6Q\T_P##"GQO_P"D
MC'Q:_P"^[/\`^-U[[X%\,7W@WPIIWAB]\1WVL2V%E'!+JNIS;[B[=5PTLA_O
M,<DXX&<#`KRO]O;]M;PK^PI\%K;XK^)?"=UK,VJ^(;'0M&M5G^RV@OKN98HG
MO;UU,5A;`G+SR<#`"AW95/0_!S4/VH]5UBXU7XY1_#RPTNX20Z;I'A"XO;V>
M'YQL9[V=84F!0$G;;QX+`9(4EG"C"F_=$>F5\^_!7_@G_P"#O@K^U#XH_:CT
MKQ_JU]J/B@WYN=*NX(5MX/M5PD[;2HW':4"C)Z'FOH*O`OV]_P!LK4?V,M.^
M%VN6O@.Z\06OCGXLZ;X3U2#3=/N;R\MK:YM[J5KBWM[96DGD0VZ_(%)VEC@X
MISI0J-.2O;5#3:/?:*^.O'/_``5+6#_@H-\!?V-_A[\+M8;2OBS;^)9-;UKQ
M=X0UC1+BP;3;`7,0M4OK>%;@.25?&[9QG&X9^Q:T$<)^TE\"]+_:0^"VN?!7
M6]=N=-M-=ABCFOK.-6EB"31R@J'RIR8P.?6J'[*7[..B_LI_!O3_`(,>'/$E
MYJ]I87-S,E]J"(LKF:9I2"$`7`+8&!VKTJBLO8P]IS]=@"O)OVPOV4O#_P"V
M)\*XOA3XG\57^C6T.KPZ@MYIL4;R%HTD4)B0$8/F'/?BO6:^:OV4/VX/%O[0
M7[<7[2/[*.M>!]-T[3O@AJOAZTTG5;2>1I]274=/:Z=IE;Y4*,NT;>HZU<X1
MJ1<9;,#U7]F'X`Z-^S'\%='^"V@>(+O5+31S.8KZ^1%ED\V>28[@@`&"Y''8
M5V/B+PUH?BS0[OPUXETJWOM/OK=X+RSNX1)%-$PPR,IX(([5?KY?_;G_`&U_
MCI^S5\=_A=\*_@G^S_;_`!"_X2[2?$>K:[I$&I&WU22STJ.S=XM.##RI;IA=
M%ECE9%?RM@=68&DJ<5%16R`J7/\`P2K^'WA'Q[<>/?V</C7XU^&$EZC"\T_P
MS?JUNY)_A64':HYPN2!GY=M:;?\`!/\`^(.N_P#$N\?_`+=_Q>U;2VYFL8=6
MALV=ARI$L,8=<'!P.O3IFN8_9K_X*E:/^U;^VYI/[/7PF\`2MX(U/X+3^,?^
M$KU..:WO8-5AU2"RN-&FM70?9Y[<2JTR,2RF6/@*P+?7]9+"T%HD5S2.<^&/
MP]3X7>!--\!6?B;5]7ATRW\F+4-?OC<W<JY)'F2D`N0#@$C.`*\C^.'[`OAO
MXV>-]3^(TGQZ^)GA_5]1M8X(SX?\5-;VMJL:D(%@5<%02S$$\L['O4G[;G[<
MFG?L@W_PT\'VG@4:YXB^*_CR#PKX634-2:PTRWN70R-)>7@AF,"[%(15C=Y'
M(4+C<R]W\$[O]HF6QNKO]H6X\$1W4XC>QL/!B7;I:`EMZ//<L#<8^4!UBBR0
M24&0!<J-.<>5K02;6QXZ?V$OVBTU163_`(*.?$[[`+7'E^7:F<S;N#O*[=FW
M(V[=V>=V.*V/@?\`\$T_@/\`!_XAM\9->O=8\:^,I)EN9/$'BVY2X=;H,2;F
M-`H"2=!NYVA1MVU]%4R6=(6568`MT!;&:A86@FG;8?-(>!@`>E%%%=!($`]1
M7%_'?X"_#;]HWX=7WPP^*6@)?:9>KD,#MEMI1]R:)^J2*>01[@@@D'M**F48
MSBXR5TP/S`USX$?MT?\`!+WX@:GXT_9W2\\7?#J>X,]S9B(W".FT?\?=O'AX
MY%'R^?'A3@%N/DKW'X(?\%J/V:/'6E6UO\7+;4/!FJLQ2Y$MJ]W9@A22ZRQ*
M6"G;@!D!!8#GK7V48%;[Q[Y%>+?%?_@GC^Q]\9RUQXP^"FD073S&22^T2,Z?
M-(Q;<Q=K<IO+$G);).37G?5<10E>A+3^5[+T\BW.,MS8C_;=_8\D0./VF_`P
MW`$`^)[8=?J]87Q#_P""C?[%GPWT;^VM2_:`T'4,Y$=KH-S]OFD([!(-V/\`
M@6`>U>0R?\$,_P!DYW++XZ\=*I8E5_M2U.T9Z<VWX5L>"?\`@BU^QKX2U+^T
MM9A\3>(@'1H[;6-9"Q(5;)XMTBW`]"&)&.W--SS-Z*$5\V*T#Q_XS_\`!83X
MG?%OQ3'\(?V'?A3>W-_?S>3:ZQJ5D)KJ4E@H>&VR4C7D'S)B0`<LJUUG[$O_
M``2PU?1O&"?M'_MC:FVN^,)KU[Z+0KF<7$,-PS!EN+F3D33`@D*,HOR]2HQ]
M=?"C]G[X,?`W3FTSX1_#71_#\;IME;3K)4DE&21OD^^^"3C<3C-=A''LSSG-
M.G@I3DIUY\S[=$'-I9!&&"C=UQS3J**]$D\S^-/[(G[/G[0GBS0O'7Q8^&\.
MH:[X7CN8_#VOVM_<65_I\=PH6=(KFVDCE1'``90V#CI6[\+/@-\'?@I:W=I\
M)OA?H'AM;Z42WS:)I,5NUW)@#S)F10TKD`99RS'')KKZ*`"N0\<_`GX2?$;X
M@^$OBMXS^'^F:EXD\"7=U<^$-:NK?-QI4ES`UO.87&"OF1,58<@\$C(!'7T4
M`-CW;`&&#5+Q1X7\/>-?#M]X1\6Z'9:GI6IV<MIJ>F:C:I/;W<$BE)(I(W!5
MT925*D$$$@U?HH`\CTW]@[]CC1;ZUO\`3?V9?!`-A<1SZ7!)X=@>#394<.'M
M864QVK%PK,T2H6959BS`$>N8`Z"BB@`(!ZBN0\-_`?X1>$OBQXC^.?AKX>:7
M8>+?%UE96GB;7K6WV7&IQ6@<6RS$</Y8D<*2,X(&<``=?10`5C?$/P#X2^*G
M@36?AIX^T2'4]"\0:7<:=K.FW`)CN[6>-HY8FP0=K(S*?8ULT4`?/OP-_P""
M6O[!7[-7Q&T[XM?`S]FS1_#GB'28Y4T[4[.\NF>W62)HG"K)*RX,;,N,<`\8
MKZ"HHH`RO&O@CPC\1_"U]X'\?>&-/UK1M3MFM]2TG5K)+BVNHFX9)(I`5=3Z
M,"*X7X5_L=?LS_!'Q.WBWX4?!'P_H5]OG:VFL;(`6`F_UR6JG*VB2'YGCA"(
M[99@3S7I]%`!7,_$'X1_#OXJW?A^[^(?A.UU27PMXABUSPZ]R"38ZA%')''<
MI@CYU2:0#.1\YXKIJ*`./\4?`;X1^,OBIX:^.'B?X?:7?^+?!]K>V_A;7[JW
MWW&EQWBQK<B$DX0R+$BD@9P",X)!Z]`0H!'.*6B@`HHHH`*Y#P1\"/A)\-/'
M?BSXF^`?A]I>E^(/'=_;WGC#6+2V"W&JS00K!"TSG);9$H55X`&<#+$GKZ*`
M"N8\1?"#X=>*OB1X?^+NN^%+:Z\2>%+6]M_#NKR9\VQBO!&MRB<XQ((8PV0?
MN#&*Z>B@#S[1OV7?@)H/[0&H?M3Z1\*]'M?B%JVAC1]4\5VUMLNKRR#QL(I2
M#A^8HOF(W8B1<X4`>@T44`<]\3?A3\-?C+X6?P-\6/A]HGB?19IHY9M)\0:5
M#>6SNC!D<QS*REE8`@XR#R,5R?PG_9`_9P^!FN/XF^$OP:T+0[]A.L-S9VOS
M6L4TGF2P6^XG[-`S_.88MD9<EMN22?3:*`"N4\?_``4^%?Q2\2^'/%WQ`^'F
MD:UJ7A&_:^\-7NIV23/IUPP`,L.X?(^%7GL54CE01U=%`!1110!'1110`444
M5+W0!1115`%%%%);`%%%%,`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
J****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
